ArticleNature communications2015
A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma.
Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed.
- Development and internal validation of a prognostic model for esophageal cancer liver metastases using the Surveillance, Epidemiology, and End Results database.Journal of thoracic disease · 2026Article
- CNet-Cox for interpretable network biomarker discovery and survival risk scoring in precise breast cancer prognosis.NPJ digital medicine · 2026Article
- Epigenomic subtypes and prognostic methylation signatures in clear cell renal cell carcinoma.Clinical epigenetics · 2026Article
- From Radiomics to Radiogenomics: Decoding Renal Cell Carcinoma Biology for Precision Medicine-a narrative review.Insights into imaging · 2025Review
- Association of MALAT1 gene polymorphisms with neuroblastoma susceptibility in children from Jiangsu Province.Human genomics · 2025Article
- TWF2 Drives Tumor Progression and Sunitinib Resistance in Renal Cell Carcinoma through Hippo Signaling Suppression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- DNA Methylation-Based Classification of Kidney Neoplasms.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025Article
- A Computational Recognition Analysis of Promising Prognostic Biomarkers in Breast, Colon and Lung Cancer Patients.International journal of molecular sciences · 2025Article
- Attenuated sex-related DNA methylation differences in cancer highlight the magnitude bias mediating existing disparities.Biology of sex differences · 2024Article
- Non-coding 886 (Epigenetics · 2024Review
- A methylation risk score for chronic kidney disease: a HyperGEN study.Scientific reports · 2024Article
- Advances in cancer DNA methylation analysis with methPLIER: use of non-negative matrix factorization and knowledge-based constraints to enhance biological interpretability.Experimental & molecular medicine · 2024Article
- Tissue of origin prediction for cancer of unknown primary using a targeted methylation sequencing panel.Clinical epigenetics · 2024Article
- Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.Cell reports. Medicine · 2023Article
- Inflammatory Networks in Renal Cell Carcinoma.Cancers · 2023Review
- EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- PITX1 plays essential functions in cancer.Frontiers in oncology · 2023Review
- Long non-coding RNAs involved in retinoblastoma.Journal of cancer research and clinical oncology · 2023Review
- SPI1 is a prognostic biomarker of immune infiltration and immunotherapy efficacy in clear cell renal cell carcinoma.Discover oncology · 2022Article
- Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma.European urology · 2022Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinomas (ccRCCs) display divergent clinical behaviours. Molecular markers might improve risk stratification of ccRCC. Here we use, based on genome-wide CpG methylation profiling, a LASSO model to develop a five-CpG-based assay for ccRCC prognosis that can be used with formalin-fixed paraffin-embedded specimens. The five-CpG-based classifier was validated in three independent sets from China, United States and the Cancer Genome Atlas data set. The classifier predicts the overall survival of ccRCC patients (hazard ratio=2.96-4.82; P=3.9 × 10(-6)-2.2 × 10(-9)), independent of standard clinical prognostic factors. The five-CpG-based classifier successfully categorizes patients into high-risk and low-risk groups, with significant differences of clinical outcome in respective clinical stages and individual 'stage, size, grade and necrosis' scores. Moreover, methylation at the five CpGs correlates with expression of five genes: PITX1, FOXE3, TWF2, EHBP1L1 and RIN1. Our five-CpG-based classifier is a practical and reliable prognostic tool for ccRCC that can add prognostic value to the staging system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.